Michael Zand – Page 401

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 … – Nasdaq

2018-03-15 Michael Zand NEWS

Pipeline Analysis Report on Stem Cell Therapy for Diabetes and Related Conditions – Major Players are Athersys … – Medgadget (blog)

Pipeline Analysis Report on Stem Cell Therapy for Diabetes and Related Conditions – Major Players are Athersys …Medgadget (blog)The report covers the present scenario and the growth prospects of the stem cell therapy for diabetes and related conditio… Continue reading

2018-03-15 Michael Zand NEWS

Scientists Use Big Data to Awaken Stem Cells and Heal Brain Tissue – Interesting Engineering

Interesting EngineeringScientists Use Big Data to Awaken Stem Cells and Heal Brain TissueInteresting EngineeringResearchers have been using the latest technology in data analysis to enlist stem cells to boost tissue repair as well as providing a road m… Continue reading

2018-03-15 Michael Zand NEWS

Current 2018 and Future 2023 Scope of Biohacking Market is Estimated to Grow 19.42% by Forecast year – Medgadget (blog)

Herald KeeperCurrent 2018 and Future 2023 Scope of Biohacking Market is Estimated to Grow 19.42% by Forecast yearMedgadget (blog)Market Research Future has a cooked research report on the global biohacking market. The global biohacking market is growin… Continue reading

2018-03-15 Michael Zand NEWS

Contrasting NewLink Genetics (NASDAQ:NLNK) and Editas Medicine (EDIT) – Dispatch Tribunal

Contrasting NewLink Genetics (NASDAQ:NLNK) and Editas Medicine (EDIT)Dispatch TribunalIt is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic … Continue reading

2018-03-15 Michael Zand NEWS

Pacific Bio (PACB) Says Study Demonstrates Potential for SMRT Sequencing to Improve Safety of Gene Therapy … – StreetInsider.com

Pacific Bio (PACB) Says Study Demonstrates Potential for SMRT Sequencing to Improve Safety of Gene Therapy …StreetInsider.comGene therapy involves replacing a defective, disease-causing DNA sequence with a normal sequence to treat or even cure the co… Continue reading

2018-03-15 Michael Zand NEWS

Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols – GlobeNewswire (press release)

Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy ProtocolsGlobeNewswire (press release)MENLO PARK, Calif., March 15, 2018 (GLOBE NEWSWIRE) — A new publication in the journal of the American Society of Gene & … Continue reading

2018-03-15 Michael Zand NEWS

Amryt Pharmaceuticals PLC licenses gene therapy platform from … – Proactive Investors UK

Proactive Investors UKAmryt Pharmaceuticals PLC licenses gene therapy platform from …Proactive Investors UKAmryt Pharma PLC (LON:AMYT) has licensed a non-viral gene therapy platform technology with potential applicability across a range of genetic di… Continue reading

2018-03-15 Michael Zand NEWS

1
…
399
400
401
402
403
…
3,823

EconoTimes

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 …
Nasdaq
NEW YORK and CLEVELAND, March 15, 2018 (GLOBE NEWSWIRE) — Abeona Therapeutics Inc. (NASDAQ:ABEO), a leading clinical-stage biopharmaceutical company focused on developing novel cell and gene therapies for life-threatening rare genetic diseases …
Abeona’s ABO-202 nabs Rare Pediatric Disease Designation in US for Batten disease; shares up 4% premarketSeeking Alpha

all 4 news articles »

Login

Cart

All posts by: Michael Zand

Abeona Therapeutics Receives FDA Rare Pediatric Disease Designation for ABO-202 Gene Therapy Program in CLN1 … – Nasdaq

Pipeline Analysis Report on Stem Cell Therapy for Diabetes and Related Conditions – Major Players are Athersys … – Medgadget (blog)

Scientists Use Big Data to Awaken Stem Cells and Heal Brain Tissue – Interesting Engineering

Current 2018 and Future 2023 Scope of Biohacking Market is Estimated to Grow 19.42% by Forecast year – Medgadget (blog)

Contrasting NewLink Genetics (NASDAQ:NLNK) and Editas Medicine (EDIT) – Dispatch Tribunal

Pacific Bio (PACB) Says Study Demonstrates Potential for SMRT Sequencing to Improve Safety of Gene Therapy … – StreetInsider.com

Study Demonstrates Potential for SMRT Sequencing to Improve the Safety of Gene Therapy Protocols – GlobeNewswire (press release)

Amryt Pharmaceuticals PLC licenses gene therapy platform from … – Proactive Investors UK